What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Gene
His primary areas of investigation include Internal medicine, Myeloid leukemia, Leukemia, Immunology and Imatinib mesylate.
His Internal medicine research is multidisciplinary, incorporating elements of Gastroenterology, Surgery and Oncology.
His work deals with themes such as Young adult, Molecular biology, Fusion gene and Fusion protein, which intersect with Myeloid leukemia.
His Leukemia research incorporates themes from Myeloid, Cancer research and Bone marrow.
John M. Goldman interconnects Stem cell and Cumulative incidence in the investigation of issues within Immunology.
His Imatinib mesylate study contributes to a more complete understanding of Imatinib.
His most cited work include:
- Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia (2888 citations)
- Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia (2837 citations)
- Graft-versus-leukemia reactions after bone marrow transplantation (2452 citations)
What are the main themes of his work throughout his whole career to date?
The scientist’s investigation covers issues in Immunology, Internal medicine, Myeloid leukemia, Leukemia and Cancer research.
His Immunology research is multidisciplinary, relying on both Progenitor cell and Stem cell.
The concepts of his Internal medicine study are interwoven with issues in Gastroenterology, Surgery and Oncology.
His work in Myeloid leukemia addresses subjects such as ABL, which are connected to disciplines such as Minimal residual disease.
John M. Goldman has researched Cancer research in several fields, including Gene and Philadelphia chromosome.
His study on Imatinib mesylate and Dasatinib is often connected to In patient as part of broader study in Imatinib.
He most often published in these fields:
- Immunology (41.68%)
- Internal medicine (36.38%)
- Myeloid leukemia (31.22%)
What were the highlights of his more recent work (between 2009-2020)?
- Internal medicine (36.38%)
- Myeloid leukemia (31.22%)
- Immunology (41.68%)
In recent papers he was focusing on the following fields of study:
John M. Goldman spends much of his time researching Internal medicine, Myeloid leukemia, Immunology, Imatinib and Oncology.
His studies in Myeloid leukemia integrate themes in fields like Tyrosine kinase, ABL, Leukemia and Tyrosine-kinase inhibitor.
He works mostly in the field of Leukemia, limiting it down to topics relating to breakpoint cluster region and, in certain cases, Real-time polymerase chain reaction, as a part of the same area of interest.
His Immunology research includes themes of Stem cell and Cohort.
His studies deal with areas such as Cancer, Newly diagnosed, Discontinuation and Genotype as well as Imatinib.
John M. Goldman focuses mostly in the field of Oncology, narrowing it down to matters related to Disease and, in some cases, Philadelphia chromosome.
Between 2009 and 2020, his most popular works were:
- European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013 (1271 citations)
- Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib (644 citations)
- The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts (452 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Gene
John M. Goldman mostly deals with Myeloid leukemia, Immunology, Internal medicine, Imatinib and Leukemia.
His Myeloid leukemia research includes elements of Discontinuation, Cancer drugs, Young adult, ABL and Alternative medicine.
His research integrates issues of Cancer research, Stem cell, Cumulative incidence and Ceramide in his study of Immunology.
His research links Oncology with Internal medicine.
His research in Imatinib intersects with topics in Tyrosine kinase and Cancer.
His work on Chronic myelogenous leukemia and Myelogenous as part of general Leukemia research is often related to Large group, thus linking different fields of science.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
